$204 Billion
The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.$11.8 Billion
Total revenue in the last quarter.$3.43 Billion
Net income is all revenues minus all expenses including taxes and interest in the last quarter.$1.56
Earnings per share is the amount of net income that is attributed to each single share outstanding.$1.52 (4.14%)
Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).23.46x
The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.$3.53 Billion
Earnings before interest expenses and taxes in the last quarter.88,300
The number of full time employees.Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
US drugmaker Pfizer Inc is hoping to rapidly roll out its experimental COVID-19 vaccine around Latin America soon after it gets emergency authorization in the United States, a senior executive said...
A major milestone in the race for a vaccine to counter Covid-19 was reached on Wednesday, when the first vaccine developers to complete phase 3 trials announced results in what has been the fastest...
Healthcare providers will be able to source products from manufacturers like BioNTech/Pfizer and Astrazeneca/Oxford to sell to customers, but any such orders will be put at the 'back of the queue'.
